Eli Lilly CDR (CAD Hedged)
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
- Conditions
- ObesityOverweight and Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06230523
- Locations
- πΊπΈ
Headlands Research - Detroit, Southfield, Michigan, United States
πΊπΈArcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy, Michigan, United States
πΊπΈStudyMetrix Research, Saint Peters, Missouri, United States
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 200
- Registration Number
- NCT06220669
- Locations
- π©πͺ
Universitatsklinikum Leipzig, Leipzig, Sachsen, Germany
πΊπΈHealthcare Innovations Institute, LLC, Coral Springs, Florida, United States
πΊπΈRoyal Palm Medical Group, Fort Myers, Florida, United States
A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06215430
- Locations
- πΊπΈ
Covance Clinical Research Unit, Dallas, Texas, United States
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 31
- Registration Number
- NCT06215521
- Locations
- πΊπΈ
Covance Clinical Research Unit 1341 Mockingbird Lane, Dallas, Texas, United States
πΊπΈCovance Clinical Research Unit 3402 Kinsman Blvd, Madison, Wisconsin, United States
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06194214
- Locations
- πΊπΈ
Covance Clinical Research Unit, Madison, Wisconsin, United States
A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT06194500
- Locations
- π¬π§
Fortrea Clinical Research Unit, Holbeck, Leeds, United Kingdom
A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 888
- Registration Number
- NCT06192108
- Locations
- πΊπΈ
Alliance Research Institute - Canoga Park, Canoga Park, California, United States
πΊπΈArk Clinical Research, Long Beach, California, United States
πΊπΈCollaborative Neuroscience Research, LLC, Los Alamitos, California, United States
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 36
- Registration Number
- NCT06190691
- Locations
- πΊπΈ
Orlando Clinical Research Center, Orlando, Florida, United States
πΊπΈPinnacle Clinical Research, San Antonio, Texas, United States
πΊπΈOrange County Research Institute, Anaheim, California, United States
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 16
- Registration Number
- NCT06190678
- Locations
- πΊπΈ
Riverside Clinical Research, Edgewater, Florida, United States
πΊπΈOrange County Research Institute, Anaheim, California, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants
- Conditions
- HealthyObeseOverweight
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 50
- Registration Number
- NCT06186622
- Locations
- πΊπΈ
Fortrea Clinical Research Unit Inc., Dallas, Texas, United States